Drugs / MOB015B
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06369727 | Oct 2017 → Feb 2018 | — | Moberg Pharma AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01814020 | Dec 2012 → Jul 2014 | tinea unguium | Moberg Pharma AB | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02866032 | Sep 2016 → Jun 2020 | tinea unguium | Moberg Pharma AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOB015B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02866032 ↗ |
| Route | Topical | “topical MOB015B” NCT01814020 ↗ |